within Pharmacolibrary.Drugs.ATC.N;

model N05AB01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.25,
    Cl             = 0.3,
    adminDuration  = 600,
    adminMass      = 0.05,
    adminCount     = 1,
    Vd             = 0.015,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0006666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Dixyrazine is a first-generation antipsychotic of the phenothiazine class, related to chlorpromazine. It has sedative, antiemetic, and antipsychotic properties, and was historically used for the treatment of psychoses such as schizophrenia as well as for agitation and nausea. It is largely obsolete and is not widely approved or used in most countries today.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for adult patients, as no published pharmacokinetic studies were found for dixyrazine.</p><h4>References</h4><ol><li><p>Liedholm, H, et al., &amp; Wåhlin-Boll, E (1985). Pharmacokinetics of dixyrazine: low bioavailability, improved by food intake. <i>Drug-nutrient interactions</i> 3(2) 87–92. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3987521/&quot;>https://pubmed.ncbi.nlm.nih.gov/3987521</a></p></li><li><p>Melander, A, &amp; McLean, A (1983). Influence of food intake on presystemic clearance of drugs. <i>Clinical pharmacokinetics</i> 8(4) 286–296. DOI:<a href=&quot;https://doi.org/10.2165/00003088-198308040-00002&quot;>10.2165/00003088-198308040-00002</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/6352137/&quot;>https://pubmed.ncbi.nlm.nih.gov/6352137</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end N05AB01;
